An Unusual Complication of Cabergoline Treatment of Macroprolactinomas

IF 0.6 Q4 ENDOCRINOLOGY & METABOLISM
A. Moumen, S. Chakdoufi, Hamza El jadi, O. Zammani, Cherif Abad El Asri, G. Belmejdoub
{"title":"An Unusual Complication of Cabergoline Treatment of Macroprolactinomas","authors":"A. Moumen, S. Chakdoufi, Hamza El jadi, O. Zammani, Cherif Abad El Asri, G. Belmejdoub","doi":"10.14740/JEM.V11I2.730","DOIUrl":null,"url":null,"abstract":"Dopamine agonist (DA) treatment is the first choice treatment of prolactinomas. Optic chiasm prolapse with secondary visual deterioration is an unusual and rare complication of DA treatment. A 40-year-old man with giant prolactinoma was successfully treated by cabergoline. After 14 months, he presented with a visual impairment with no ophthalmologic anomalies that could explain this worsening. The pituitary magnetic resonance imaging (MRI) revealed an important shrinkage of prolactinoma with a prolapse and a central atrophy of optic chiasm secondary to the adenoma shrinkage. This case highlights the need of regular assessment of visual field all along cabergoline treatment of macroprolactinomas despite initial improvement or even normalization of visual field, to promptly identify an optic chiasm prolapse and avoid the optic chiasm atrophy. J Endocrinol Metab. 2021;11(2):52-55 doi: https://doi.org/10.14740/jem730","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2021-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endocrinology and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/JEM.V11I2.730","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Dopamine agonist (DA) treatment is the first choice treatment of prolactinomas. Optic chiasm prolapse with secondary visual deterioration is an unusual and rare complication of DA treatment. A 40-year-old man with giant prolactinoma was successfully treated by cabergoline. After 14 months, he presented with a visual impairment with no ophthalmologic anomalies that could explain this worsening. The pituitary magnetic resonance imaging (MRI) revealed an important shrinkage of prolactinoma with a prolapse and a central atrophy of optic chiasm secondary to the adenoma shrinkage. This case highlights the need of regular assessment of visual field all along cabergoline treatment of macroprolactinomas despite initial improvement or even normalization of visual field, to promptly identify an optic chiasm prolapse and avoid the optic chiasm atrophy. J Endocrinol Metab. 2021;11(2):52-55 doi: https://doi.org/10.14740/jem730
卡麦角林治疗巨催乳素瘤的罕见并发症
多巴胺激动剂(DA)治疗是泌乳素瘤的首选治疗方法。视交叉脱垂伴继发性视力下降是DA治疗的罕见并发症。一名患有巨大泌乳素瘤的40岁男子成功地接受了卡麦角林的治疗。14个月后,他出现了视力障碍,没有眼科异常,这可以解释这种恶化。垂体磁共振成像(MRI)显示泌乳素瘤有一个重要的缩小,伴有脱垂和继发于腺瘤缩小的视交叉中央萎缩。该病例强调,尽管视野最初有所改善甚至正常化,但在卡麦角林治疗大泌乳素瘤的过程中,需要定期评估视野,以及时发现视交叉脱垂并避免视交叉萎缩。内分泌代谢杂志。2021年;11(2):52-55 doi:https://doi.org/10.14740/jem730
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Endocrinology and Metabolism
Journal of Endocrinology and Metabolism ENDOCRINOLOGY & METABOLISM-
CiteScore
0.70
自引率
0.00%
发文量
21
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信